These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7217960)

  • 1. Double-blind comparison of single doses of DS103-282, baclofen and placebo for suppression of spasticity.
    Hassan N; McLellan DL
    J Neurol Neurosurg Psychiatry; 1980 Dec; 43(12):1132-6. PubMed ID: 7217960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The assessment of drug treatment of spastic gait.
    Corston RN; Johnson F; Godwin-Austen RB
    J Neurol Neurosurg Psychiatry; 1981 Nov; 44(11):1035-9. PubMed ID: 7038051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen.
    Stien R; Nordal HJ; Oftedal SI; Slettebø M
    Acta Neurol Scand; 1987 Mar; 75(3):190-4. PubMed ID: 3554879
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
    Smolenski C; Muff S; Smolenski-Kautz S
    Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
    Groves L; Shellenberger MK; Davis CS
    Adv Ther; 1998; 15(4):241-51. PubMed ID: 10186943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tizanidine versus baclofen in the treatment of spasticity in multiple sclerosis patients.
    Hoogstraten MC; van der Ploeg RJ; vd Burg W; Vreeling A; van Marle S; Minderhoud JM
    Acta Neurol Scand; 1988 Mar; 77(3):224-30. PubMed ID: 3376747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative double-blind study of the effectiveness and tolerance of baclofen, tetrazepam and tizanidine in spastic movement disorders of the lower extremities].
    Pellkofer M; Paulig M
    Med Klin (Munich); 1989 Jan; 84(1):5-8. PubMed ID: 2645508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis.
    Eyssette M; Rohmer F; Serratrice G; Warter JM; Boisson D
    Curr Med Res Opin; 1988; 10(10):699-708. PubMed ID: 3286128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tizanidine in the treatment of spasticity.
    Newman PM; Nogues M; Newman PK; Weightman D; Hudgson P
    Eur J Clin Pharmacol; 1982; 23(1):31-5. PubMed ID: 6751834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrathecal baclofen for spasticity in cerebral palsy.
    Albright AL; Cervi A; Singletary J
    JAMA; 1991 Mar; 265(11):1418-22. PubMed ID: 1999883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of spasticity with tizanidine in multiple sclerosis.
    Lapierre Y; Bouchard S; Tansey C; Gendron D; Barkas WJ; Francis GS
    Can J Neurol Sci; 1987 Aug; 14(3 Suppl):513-7. PubMed ID: 3676923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C0-contraction and stretch reflexes in spasticity during treatment with baclofen.
    McLellan DL
    J Neurol Neurosurg Psychiatry; 1977 Jan; 40(1):30-8. PubMed ID: 845604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tizanidine versus baclofen in the treatment of spasticity in patients with multiple sclerosis.
    Bass B; Weinshenker B; Rice GP; Noseworthy JH; Cameron MG; Hader W; Bouchard S; Ebers GC
    Can J Neurol Sci; 1988 Feb; 15(1):15-9. PubMed ID: 3345456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of eperisone and baclofen in spastic palsy: a double-blind randomized trial.
    Bresolin N; Zucca C; Pecori A
    Adv Ther; 2009 May; 26(5):563-73. PubMed ID: 19458926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of baclofen in treatment of spasticity in multiple sclerosis.
    Sawa GM; Paty DW
    Can J Neurol Sci; 1979 Aug; 6(3):351-4. PubMed ID: 385132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baclofen for spasticity in multiple sclerosis. Double-blind crossover and three-year study.
    Feldman RG; Kelly-Hayes M; Conomy JP; Foley JM
    Neurology; 1978 Nov; 28(11):1094-8. PubMed ID: 362234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group.
    Neurology; 1994 Nov; 44(11 Suppl 9):S70-8. PubMed ID: 7970014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacological treatment of spasticity in multiple sclerosis].
    Heinzlef O; Monteil-Roch I
    Rev Neurol (Paris); 2012 Apr; 168 Suppl 3():S62-8. PubMed ID: 22721367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of baclofen on gait in spastic MS patients.
    Orsnes GB; Sørensen PS; Larsen TK; Ravnborg M
    Acta Neurol Scand; 2000 Apr; 101(4):244-8. PubMed ID: 10770520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind, long-term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions.
    Medici M; Pebet M; Ciblis D
    Curr Med Res Opin; 1989; 11(6):398-407. PubMed ID: 2651016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.